Insiders · Profile

Tessier-Lavigne Marc

Director at Denali Therapeutics · Director at Regeneron Pharmaceuticals · Director at AGIOS PHARMACEUTICALS. Filing since 6 May 2013. CIK 0001437435

DNLI Denali Therapeutics Inc. Director · 17 trades REGN Regeneron Pharmaceuticals Director · 14 trades AGIO AGIOS PHARMACEUTICALS, INC. Director · 1 trade

Company

Date

Role

Action

Shares

Amount

Of holding

DNLI Denali Therapeutics Inc.

23 Nov 2022

Director

Sold, plan not stated

20,000

$609.60K

1.1%

DNLI Denali Therapeutics Inc.

2 Nov 2022

Director

Sold, plan not stated

11,252

$341.27K

0.6%

DNLI Denali Therapeutics Inc.

1 Nov 2022

Director

Sold, plan not stated

8,748

$264.19K

0.5%

REGN Regeneron Pharmaceuticals

3 Oct 2022

Director

Sold, plan not stated

3,612

$2.59M

61.4%

REGN Regeneron Pharmaceuticals

30 Sep 2022

Director

Sold, plan not stated

3,428

$2.39M

60.2%

REGN Regeneron Pharmaceuticals

29 Sep 2022

Director

Sold, plan not stated

3,798

$2.62M

62.6%

DNLI Denali Therapeutics Inc.

28 Sep 2022

Director

Sold, plan not stated

20,000

$616.30K

1.0%

DNLI Denali Therapeutics Inc.

23 Aug 2022

Director

Sold, plan not stated

20,000

$632.28K

1.0%

DNLI Denali Therapeutics Inc.

25 Jul 2022

Director

Sold, plan not stated

20,000

$712.11K

1.0%

DNLI Denali Therapeutics Inc.

23 Mar 2022

Director

Sold, plan not stated

20,000

$676.58K

1.0%

REGN Regeneron Pharmaceuticals

21 Mar 2022

Director

Sold, plan not stated

7,439

$5.13M

76.6%

REGN Regeneron Pharmaceuticals

17 Mar 2022

Director

Sold, plan not stated

7,830

$5.32M

77.5%

REGN Regeneron Pharmaceuticals

16 Mar 2022

Director

Sold, plan not stated

4,361

$2.94M

65.8%

DNLI Denali Therapeutics Inc.

30 Dec 2021

Director

Sold, plan not stated

20,047

$909.36K

20.3%

DNLI Denali Therapeutics Inc.

29 Dec 2021

Director

Sold, plan not stated

32,104

$1.41M

27.3%

DNLI Denali Therapeutics Inc.

28 Dec 2021

Director

Sold, plan not stated

10,980

$487.22K

10.2%

REGN Regeneron Pharmaceuticals

9 Dec 2021

Director

Sold, plan not stated

3,784

$2.52M

64.6%

REGN Regeneron Pharmaceuticals

13 Sep 2021

Director

Sold, plan not stated

12,750

$8.18M

86.0%

DNLI Denali Therapeutics Inc.

7 Jun 2021

Director

Sold, plan not stated

94,378

$6.64M

3.6%

DNLI Denali Therapeutics Inc.

24 May 2021

Director

Sold, plan not stated

8,806

$528.58K

0.3%

DNLI Denali Therapeutics Inc.

21 May 2021

Director

Sold, plan not stated

37,957

$2.28M

1.5%

DNLI Denali Therapeutics Inc.

3 May 2021

Director

Sold, plan not stated

3,237

$194.59K

0.1%

DNLI Denali Therapeutics Inc.

1 Apr 2021

Director

Sold, plan not stated

50,000

$2.83M

1.9%

DNLI Denali Therapeutics Inc.

1 Mar 2021

Director

Sold, plan not stated

100,000

$6.62M

3.6%

DNLI Denali Therapeutics Inc.

16 Jun 2020

Director

Sold, plan not stated

400,000

$10.44M

12.7%

REGN Regeneron Pharmaceuticals

6 May 2020

Director

Sold, plan not stated

15,000

$8.46M

89.1%

REGN Regeneron Pharmaceuticals

13 Feb 2020

Director

Sold, plan not stated

14,279

$5.71M

88.6%

REGN Regeneron Pharmaceuticals

5 Aug 2015

Director

Sold, plan not stated

5,000

$2.95M

80.8%

REGN Regeneron Pharmaceuticals

26 Feb 2015

Director

Sold, plan not stated

3,000

$1.27M

71.7%

REGN Regeneron Pharmaceuticals

27 Aug 2014

Director

Sold, plan not stated

3,000

$1.06M

71.7%

AGIO AGIOS PHARMACEUTICALS, INC.

24 Jul 2013

Director

Bought

55,555

$999.99K

122%

REGN Regeneron Pharmaceuticals

6 May 2013

Director

Sold, plan not stated

13,334

$3.48M

100%

32 decisions on file.